{
  "metadata": {
    "case_id": 17,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-28T06:06:04.972363",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/17_NCT03036293.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/17_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.96,
          0.78,
          0.3
        ],
        [
          0.4,
          0.62,
          0.88
        ],
        [
          0.78,
          0.93,
          0.2
        ],
        [
          0.4,
          0.78,
          0.7
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Tenoten, 2 tablets twice daily (4 tablets/day)",
            "type": "EXPERIMENTAL",
            "description": "Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.",
            "interventionNames": [
              "Drug: Tenoten"
            ]
          },
          "pred_item": {
            "label": "Tenoten Group 1",
            "type": "EXPERIMENTAL",
            "description": "Patients received Tenoten in the regimen of 2 pills 2 times a day (4 tablets/day) for 12 weeks.",
            "interventionNames": [
              "Drug: Tenoten"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.88,
          "status": "matched",
          "ref_item": {
            "label": "Placebo, 2 tablets twice daily (4 tablets/day)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.",
            "interventionNames": [
              "Drug: Placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo Groups 2 and 4",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients received placebo in dosages similar to Tenoten (2 pills 2 times a day or 2 pills 4 times a day, respectively) for 12 weeks. These groups were combined for analysis.",
            "interventionNames": [
              "Drug: Placebo"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "label": "Tenoten, 2 tablets 4 times daily (8 tablets/day)",
            "type": "EXPERIMENTAL",
            "description": "Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.",
            "interventionNames": [
              "Drug: Tenoten"
            ]
          },
          "pred_item": {
            "label": "Tenoten Group 3",
            "type": "EXPERIMENTAL",
            "description": "Patients received Tenoten in the regimen of 2 pills 4 times a day (8 tablets/day) for 12 weeks.",
            "interventionNames": [
              "Drug: Tenoten"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Placebo, 2 tablets 4 times daily (8 tablets/day)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.",
            "interventionNames": [
              "Drug: Placebo"
            ]
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.9,
          0.3
        ],
        [
          0.3,
          0.94
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Tenoten",
            "description": "Tablet for oral use.",
            "armGroupLabels": [
              "Tenoten, 2 tablets 4 times daily (8 tablets/day)",
              "Tenoten, 2 tablets twice daily (4 tablets/day)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Tenoten",
            "description": "Anxiolytic drug that contains highly diluted antibodies to S100 protein (HD Abs to S100).",
            "armGroupLabels": [
              "Tenoten Group 1",
              "Tenoten Group 3"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Tablet for oral use.",
            "armGroupLabels": [
              "Placebo, 2 tablets 4 times daily (8 tablets/day)",
              "Placebo, 2 tablets twice daily (4 tablets/day)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Preparations that looked the same and had similar organoleptic properties to Tenoten.",
            "armGroupLabels": [
              "Placebo Groups 2 and 4"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "Change From Baseline in the Mean HAM-A Score at 12 Weeks of Treatment: 1. Group 1 (Tenoten®, 4 Tablets a Day); 2. Group 3 (Tenoten®, 8 Tablets a Day).",
            "description": "The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome",
            "timeFrame": "12 weeks"
          },
          "pred_item": {
            "measure": "Change from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score",
            "description": "The HAM-A is a clinical rating scale designed to measure the severity of a patient's anxiety disorders. It contains 14 statements with 5 response options from 0 to 4 which are correlated with the severity of anxiety. The sum of points of 13 or less means the absence of anxiety, 14–17 points—mild severity, 18–24 points—moderate severity, and more than 25 points—severe anxiety disorder.",
            "timeFrame": "12 weeks"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 6,
      "pred_count": 5,
      "similarity_matrix": [
        [
          0.9,
          0.72,
          0.45,
          0.32,
          0.15
        ],
        [
          0.78,
          0.7,
          0.78,
          0.15,
          0.2
        ],
        [
          0.78,
          0.95,
          0.72,
          0.18,
          0.22
        ],
        [
          0.78,
          0.7,
          0.96,
          0.3,
          0.28
        ],
        [
          0.3,
          0.15,
          0.15,
          0.9,
          0.25
        ],
        [
          0.42,
          0.4,
          0.18,
          0.15,
          0.77
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Change From Baseline in the Mean HAM-A Score at 4 Weeks of Treatment: 1.1. Group 1 (Tenoten®, 4 Tablets a Day); 1.2. Group 3 (Tenoten®, 8 Tablets a Day).",
            "description": "The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome",
            "timeFrame": "4 weeks"
          },
          "pred_item": {
            "measure": "Change from baseline in the mean HAM-A score",
            "description": "Assessment of anxiety severity at intermediate time points.",
            "timeFrame": "4 and 8 weeks"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "The Mean HAM-A Score at 8 Weeks of Treatment: 2.1. Group 1 (Tenoten®, 4 Tablets a Day); 2.2. Group 3 (Tenoten®, 8 Tablets a Day).",
            "description": "The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome",
            "timeFrame": "8 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Patients Had at Least a 50% Improvement in the HAM-A Score: 3.1. Group 1 (Tenoten® 4 Tablets a Day): After 4, 8 and 12 Weeks; 3.2. Group 3 (Tenoten® 8 Tablets a Day): After 4, 8 and 12 Weeks.",
            "description": "The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome",
            "timeFrame": "4,8,12 weeks"
          },
          "pred_item": {
            "measure": "Percentage of patients who responded to treatment",
            "description": "Response defined as ≥ 50% reduction on HAM-A score.",
            "timeFrame": "4, 8, and 12 weeks"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Patients With no Anxiety (HAM-A Score <14) in: 4.1. Group 1 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks; 4.3. Group 3 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks.",
            "description": "The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome",
            "timeFrame": "4,8,12 weeks"
          },
          "pred_item": {
            "measure": "Percentage of patients without anxiety (remission)",
            "description": "Remission defined as HAM-A score < 14.",
            "timeFrame": "4, 8, and 12 weeks"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 3,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Change From Baseline in the Total EQ-5D-3L Score at 12 Weeks of Treatment in Patients From: 5.1. Group 1 (Tenoten®, 4 Tablets a Day); 5.2. Group 3 (Tenoten®, 8 Tablets a Day).",
            "description": "European Quality of Life Instrument questionnaire (EQ-5D-3L) is designed for the evaluation of the quality of life.The score ranges between 5-15. Higher values represent a worse outcome.",
            "timeFrame": "12 weeks"
          },
          "pred_item": {
            "measure": "Change from baseline in the EQ-5D-3L scores",
            "description": "The European Quality of Life Instrument (EQ-5D-3L) comprises five criteria: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.",
            "timeFrame": "12 weeks"
          }
        },
        {
          "ref_idx": 5,
          "pred_idx": 4,
          "score": 0.77,
          "status": "matched",
          "ref_item": {
            "measure": "Total CGI Scores in Patients From: 6.1. Group 1 (Tenoten®, 4 Tablets a Day); 6.2. Group 3 (Tenoten®, 8 Tablets a Day).",
            "description": "Clinical Global Impession (CGI) provides a brief assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. Total range 0-16. Higher values represent a worse outcome",
            "timeFrame": "12 weeks"
          },
          "pred_item": {
            "measure": "Clinical Global Impression-Efficacy Index (CGI-EI) score",
            "description": "Assesses the patient’s impression of the ratio between therapeutic effects and side effects. Scores range from 0 (marked improvement and no side effects) to 4 (unchanged or worse and side effects outweigh therapeutic effects).",
            "timeFrame": "12 weeks"
          }
        }
      ]
    }
  ]
}